Asset
RISLENEMDAZ
Avalo Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01941043 | phase2 | completed | 2013-11-01 | 2014-09-01 | Avalo Therapeutics, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment |
| NCT02459236 | phase2 | completed | 2015-06-01 | 2016-09-01 | Avalo Therapeutics, Inc. | A Study of Intermittent Doses of CERC-301 in MDD |
FDA applications (0)
This company has no applications containing this asset.